8-K: Turning Point Brands Q2 2026: Modern Oral Surges, Profitability Dips

Turning Point Brands reported a 22.6% increase in Q2 2026 net sales driven by Modern Oral growth, but net income and Adjusted EBITDA saw significant declines.

Summary

• Turning Point Brands announced its financial results for the second quarter ended June 30, 2026.
• Total consolidated net sales increased by 22.6% to $142.9 million.
• The Modern Oral segment saw substantial growth, with gross revenue up 149% to $87.0 million and net sales up 128% to $68.4 million, now representing 48% of total company net sales.
• The Stoker's segment net sales increased by 54.5% to $107.6 million.
• The Zig-Zag segment net sales decreased by 3.5% to $35.4 million.
• Gross profit increased by 40.6% to $93.7 million, though adjusted for a tariff refund, it was $81.5 million.
• Net income decreased significantly by 75.2% to $3.6 million.
• Adjusted EBITDA decreased by 50.0% to $15.2 million, attributed to strategic sales and marketing investments.
• Diluted EPS was $0.18, and Adjusted Diluted EPS was $0.23, down from $0.79 and $0.98 respectively in the prior year.
• The company raised its FY 2026 guidance for Modern Oral Gross and Net Sales.
• Ending cash was $268.3 million, with net debt of $31.7 million, and total liquidity of $339.0 million.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed result, with strong top-line growth in a key segment offset by significant declines in net income and adjusted EBITDA, alongside increased operating expenses.

Positives

• Total consolidated net sales increased by 22.6% to $142.9 million.
• Modern Oral segment gross revenue increased 149% to $87.0 million and net sales increased 128% to $68.4 million, now accounting for 48% of total company net sales.
• Stoker's segment net sales increased by 54.5% to $107.6 million.
• Gross profit increased by 40.6% to $93.7 million.
• The company raised its full-year guidance for Modern Oral Gross Sales to $330-$350 million and Net Sales to $260-$270 million.
• Ending cash balance increased to $268.3 million.
• Total liquidity stands at $339.0 million.

Negatives

• Net income decreased by 75.2% to $3.6 million.
• Adjusted EBITDA decreased by 50.0% to $15.2 million.
• Diluted EPS fell to $0.18 from $0.79 in the prior year.
• Adjusted Diluted EPS fell to $0.23 from $0.98 in the prior year.
• Consolidated selling, general, and administrative (SG&A) expenses increased significantly by 91.1% to $76.9 million.
• Zig-Zag segment net sales decreased by 3.5% to $35.4 million.
• Adjusted gross profit as a percentage of net sales for the Stoker's segment decreased to 56.9% from 62.5% due to higher chain penetration.

Risks

• Increased chain penetration in the Stoker's segment led to a decrease in adjusted gross profit margin.
• Significant investments in sales and marketing for Modern Oral are impacting short-term profitability.
• The company's reliance on the PMTA process for certain product lines involves ongoing costs and regulatory uncertainty.
• Potential for future differences between preliminary reported information and the final figures in the Form 10-Q.

Future Outlook

The company raised its FY 2026 guidance for Modern Oral Gross Sales to $330-$350 million (up from $280-$300 million) and Net Sales to $260-$270 million (up from $210-$225 million). Projected full-year Adjusted EBITDA is $70-$90 million, inclusive of investments in Modern Oral sales, marketing, and trade promotions.

Management Comments

• "We delivered another strong quarter, highlighted by continued growth in Modern Oral."
• "We believe our investments in retail distribution, commercial capabilities and brand development are translating into stronger consumer adoption and expanding market access for both FRE and ALP."
• "The progress we're making today positions us to capitalize on the continued shift in nicotine consumption toward modern oral to maximize long-term shareholder value."

Industry Context

StockSavvy.ai notes that the strong performance in the 'Modern Oral' segment aligns with broader industry trends of consumers shifting towards newer nicotine delivery formats. However, the decline in the established Zig-Zag segment and the significant increase in SG&A expenses, while attributed to strategic investments, warrant close monitoring for their impact on long-term profitability.

Legal Proceedings

• The company is involved in litigation related to an insurance claim, incurring non-recurring legal expenses.

Stakeholder Impact

• Shareholders: Potential concern over the significant decrease in net income and EPS, despite strong revenue growth in a key segment. The equity raise may dilute existing shareholders.
• Employees: Increased SG&A expenses could reflect investments in sales and marketing teams.
• Creditors: Net debt remains manageable, and total liquidity is strong, suggesting continued ability to service debt.

Next Steps

• Continue to invest in retail distribution, commercial capabilities, and brand development for FRE and ALP.
• Capitalize on the shift in nicotine consumption towards modern oral products.
• Participate in the earnings conference call scheduled for August 4, 2026, at 9:00 a.m. Eastern.
• File the full second quarter 2026 results in the Quarterly Report on Form 10-Q.

Key Dates

Recommendation

The significant growth in the Modern Oral segment and raised guidance are positive, but the sharp decline in net income, Adjusted EBITDA, and EPS, coupled with a substantial increase in operating expenses, presents a concerning trend. The equity raise also adds dilution. A 'hold' recommendation reflects the uncertainty between strong top-line growth and deteriorating profitability.

Keywords

Turning Point Brands, Modern Oral, Stoker's, Zig-Zag, Q2 2026, Net Sales, Adjusted EBITDA, EPS